BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37434012)

  • 1. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer.
    Chen G; Liu Y; Su D; Qiu J; Long J; Zhao F; Tao J; Yang G; Huang H; Xiao J; Zhang T; Zhao Y
    Cell Oncol (Dordr); 2023 Dec; 46(6):1691-1708. PubMed ID: 37434012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of anoikis-based molecular heterogeneity in pancreatic cancer and pancreatic neuroendocrine tumor and its association with tumor immune microenvironment and metabolic remodeling.
    Li N; Jia X; Wang Z; Wang K; Qu Z; Chi D; Sun Z; Jiang J; Cui Y; Wang C
    Front Endocrinol (Lausanne); 2023; 14():1153909. PubMed ID: 37234801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and comprehensive analysis of a novel prognostic signature associated with pyroptosis molecular subtypes in patients with pancreatic adenocarcinoma.
    Huang Q; Peng X; Li Q; Zhu J; Xue J; Jiang H
    Front Immunol; 2023; 14():1111494. PubMed ID: 36817451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 7. Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer.
    Feng Y; Li P; Yang F; Xu K
    Medicine (Baltimore); 2022 Dec; 101(51):e32364. PubMed ID: 36595826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients.
    Zhang B; Liu J; Li H; Huang B; Zhang B; Song B; Bao C; Liu Y; Wang Z
    Front Pharmacol; 2023; 14():1244752. PubMed ID: 37745080
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
    He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
    J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-omics analyses based on genes associated with oxidative stress and phospholipid metabolism revealed the intrinsic molecular characteristics of pancreatic cancer.
    Wang H; Guo H; Sun J; Wang Y
    Sci Rep; 2023 Aug; 13(1):13564. PubMed ID: 37604837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer.
    Song J; Ruze R; Chen Y; Xu R; Yin X; Wang C; Xu Q; Zhao Y
    BMC Cancer; 2022 Aug; 22(1):894. PubMed ID: 35974300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer.
    Deng GC; Sun DC; Zhou Q; Lv Y; Yan H; Han QL; Dai GH
    BMC Genomics; 2021 Nov; 22(1):791. PubMed ID: 34732125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.
    Tang P; Qu W; Wu D; Chen S; Liu M; Chen W; Ai Q; Tang H; Zhou H
    J Immunol Res; 2021; 2021():3821055. PubMed ID: 34993253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
    Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel natural killer cell-related signatures to predict prognosis and chemotherapy response of pancreatic cancer patients.
    Lan Y; Jia Q; Feng M; Zhao P; Zhu M
    Front Genet; 2023; 14():1100020. PubMed ID: 37035749
    [No Abstract]   [Full Text] [Related]  

  • 17. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer.
    Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
    Exp Biol Med (Maywood); 2022 Jan; 247(2):120-130. PubMed ID: 34632851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNAs associated with vascular mimicry establish a novel molecular subtype and prognostic model for pancreatic cancer.
    Li D; Zhang Q; Tang Y; Mao F; Zeng J; Ji A
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11571-11584. PubMed ID: 37400573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer.
    Ding C; Yu Z; Zhu J; Li X; Dai M; QiangHe
    Dis Markers; 2022; 2022():9737587. PubMed ID: 35756487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.